摘要
目的探讨华蟾素胶囊联合肿瘤供血动脉灌注化疗栓塞治疗晚期非小细胞肺癌的临床疗效。方法选取84例晚期非小细胞肺癌患者为研究对象,按照随机数表平均分成观察组和对照组,观察组患者接受华蟾素胶囊联合肿瘤供血动脉灌注化疗栓塞治疗,对照组患者接受常规肿瘤供血动脉灌注化疗栓塞治疗。治疗后对2组患者疗效进行分级统计,包括"痊愈"、"有效"、"无效"。对患者不良情况进行统计,并计算2组患者治疗有效系数、安全系数。并且对2组患者住院时间、治疗后1个月内出院率进行记录分析。结果研究发现,观察组患者"有效"治疗34例(80. 95%),较对照组[23例(54. 76%)]多。观察组治疗后发生不良反应14例(33. 33%),较对照组12例(28. 57%)多,但差异不明显。此外,对照组患者平均住院时间为(46. 28±10. 57)天,较观察组住院时间[(40. 31±9. 18)天]长,且接受治疗后1个月内出院率,观察组(61. 90%)较对照组(28. 57%)高。结论华蟾素胶囊联合肿瘤供血动脉灌注化疗栓塞治疗方案较常规肿瘤供血动脉灌注化疗栓塞治疗方案有效,疗效显著,患者基本无出现严重后遗症以及并发症,适合临床治疗推广。
Objective To explore the clinical efficacy of cinobufacini capsule combined with tumor arterial infusion chemotherapy and embolization in the treatment of advanced non-small cell lung cancer. Methods 84 patients with late stage non-small cell lung cancer were randomly divided into 2 groups,42 cases treated with cinobufacini capsule combined with tumor artery chemoembolization was the observation group,42 patients received conventional tumor feeding artery perfusion chemotherapy embolism treatment of patients in the control group.After treatment,the efficacy of the 2 groups of patients was classified,including ＂recovery＂,＂effective＂,and ＂invalid＂.The adverse events were statistically analyzed,and the effective coefficient and safety factor of the 2 groups were calculated.And the 2 groups of patients in hospital time,within 1 month after treatment,discharge rate was recorded and analyzed. Results The study found that the observation group effective treatment effect was 34 cases（80.95%）,higher than the control group of 23 cases（54.76%）.The observation group adverse reactions after treatment was 14 cases（33.33%）,higher than the control group of 12 cases（28.57%）,but the difference was not significant.In addition,patients in the control group,the average hospitalization time was（46.28±10.57） days,longer than the control group of（40.31±9.18） days,and the patients were treated within 1 months discharge rate of the patients in the observation group（61.90%）was higher than the control group（28.57%）. Conclusion Cinobufacini capsule combined with tumor artery chemoembolization for non-small cell lung cancer than the conventional tumor feeding artery chemoembolization is more effective,without severe complications,it is suitable for clinical promotion.
作者
侯春立
陈连刚
张翠红
HOU Chunli;CHEN Lian＇gang;ZHANG Cuihong.(Bethune International Peace Hospital of the People＇s Liberation Army,Shijiazhuang,05008)
出处
《实用癌症杂志》
2018年第10期1659-1661,共3页
The Practical Journal of Cancer
关键词
华蟾素胶囊
动脉灌注化疗
非小细胞肺癌
临床疗效
Cinobufacini capsule
Artery chemoembolization Chemotherapy
Non-small cell lung cancer
Clinical effect
